This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogène
This BCL9L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 147-176 amino acids from the N-terminal region of human BCL9L.
BCL9L
Reactivité: Humain
WB, ELISA
Hôte: Lapin
Polyclonal
Biotin
Indications d'application
WB: 1:1000
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Date de péremption
6 months
Miller, Rutherford, Johnson, Fiedler, Bienz: "Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor." dans: Journal of molecular biology, Vol. 401, Issue 5, pp. 969-84, (2010) (PubMed).
Fritzmann, Morkel, Besser, Budczies, Kosel, Brembeck, Stein, Fichtner, Schlag, Birchmeier: "A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential." dans: Gastroenterology, Vol. 137, Issue 1, pp. 165-75, (2009) (PubMed).
Sampietro, Dahlberg, Cho, Hinds, Kimelman, Xu: "Crystal structure of a beta-catenin/BCL9/Tcf4 complex." dans: Molecular cell, Vol. 24, Issue 2, pp. 293-300, (2006) (PubMed).
Brembeck, Schwarz-Romond, Bakkers, Wilhelm, Hammerschmidt, Birchmeier: "Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions." dans: Genes & development, Vol. 18, Issue 18, pp. 2225-30, (2004) (PubMed).
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).